IP Library Granted Patent US 10,925,968
Granted Patent B2
US 10,925,968 · App. 16/455,184 · Granted Feb 23, 2021

Cell internalizing compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,925,968
App. No.
16/455,184
Granted
Feb 23, 2021
Kind
B2
Abstract

Provided herein are cell penetrating compounds having the Formula I: where, generally, each T is a thiol reactive group (e.g., a phosphorothioate), each L is a linker (e.g., a linear alkyl), and Y is a biologic (e.g., an antibody). Also provided are pharmaceutical compositions including the cell penetrating compounds, and methods of delivering the compound into a cell.

Claims (22)

1. A compound having the Formula II:

or a pharmaceutically acceptable salt thereof, wherein:

each R is CH 3 or H;

each L is independently a polyethylene glycol (PEG), a linear alkyl, or a cyclic alkyl;

Y is a protein, an antibody, a peptide, or a nucleic acid; and

n is an integer from 5 to 25.

2. The compound of claim 1 , wherein n is an integer from 12 to 20.

3. The compound of claim 1 , wherein n is 15, 16 or 17.

4. The compound claim 1 , wherein each L is a linear alkyl.

5. The compound of claim 1 , wherein each L is independently a linear (C 2 -C 6 )alkyl, or a cyclic (C 5 -C 6 )alkyl, or —(O—CH 2 —CH 2 ) p —, wherein p is an integer from 1 to 5.

6. The compound of claim 1 , wherein each L is —CH 2 —.

7. The compound of claim 1 , wherein each L is —(O—CH 2 —CH 2 ) p —, wherein p is an integer from 1 to 5.

8. The compound of claim 1 , wherein each R is H, each L is —CH 2 —, n is 15, 16 or 17, and Y is an antibody.

9. The compound of claim 8 , wherein n is 16.

10. The compound of claim 1 , wherein Y is an antibody or antibody fragment.

11. The compound of claim 1 , wherein Y is a peptide.

12. The compound of claim 1 , wherein Y is a protein.

13. The compound of claim 1 , wherein Y is a nucleic acid.

14. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

15. A method of delivering a therapeutic agent into a cell comprising contacting a cell with a compound of claim 1 or a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the compound is internalized into the cell.

16. A pharmaceutical composition comprising the compound of claim 12 , or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

17. A method of delivering a therapeutic agent into a cell comprising contacting a cell with a compound of claim 1 or a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, wherein the compound is internalized into the cell.

Assignments (5)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2019
From: FU, YANWEN; KAUFMANN, GUNNAR F.; LEE, HEEHYOUNG; ZHU, TONG; JI, HENRY HONGJUN
To: SORRENTO THERAPEUTICS, INC.
Reel/Frame 050052/0864 →